Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

计划入组 620 人 · 首次发布于 2024 年 6 月 21 日

Trastuzumab in HER2-positive Biliary Tract Cancer

计划入组 4 人 · 首次发布于 2018 年 8 月 2 日

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

计划入组 74 人 · 首次发布于 2019 年 4 月 29 日

Biliary tract cancer diagnostic(J-Pharma Co., Ltd.)

anti-HER2 antibodies (cancer)

HER2+ Breast Cancer(Diakonos)

TRACT Therapeutics, Inc.

United States

Institute of Liver & Biliary Sciences

India

INSTITUTE OF LIVER AND BILIARY SCIENCES

India

Jazz Pharmaceuticals Acquires Global Rights to Zanidatamab in $1.76 Billion Deal with Zymeworks

Bispecific Antibodies Emerge as Promising Immunotherapy Backbone in Cancer Treatment

Zanidatamab Plus Chemotherapy Shows Promising Results in Heavily Pretreated HER2-Positive Breast Cancer